ArticlePloS one2026
High donor hemoglobin interacts with pre-transplant recipient neutropenia to modulate mortality after allogeneic hematopoietic stem cell transplantation: An exploratory, single-center, retrospective, real-world study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prognostication after allogeneic hematopoietic stem cell transplantation remains a critical challenge, and the complex interplay between recipient vulnerability and donor graft characteristics is poorly understood. The primary objective of this retrospective, hypothesis-generating study was to investigate the interaction between pre-transplant recipient neutropenia and donor hemoglobin levels on long-term survival. We performed a pragmatic, single-center, retrospective cohort study on 94 consecutive patients who underwent transplantation at a reference center in Western Iran. Using multivariable survival models, we assessed the independent and interactive effects of pre-transplant factors on 5-year overall survival, with appropriate handling of missing data. The robustness of our central finding was confirmed via sensitivity analyses. Our adjusted multivariable analysis revealed two main findings. First, higher continuous donor hemoglobin was associated with a trend toward increased mortality (Hazard Ratio per 1 g/dL increase = 1.45; 95% Confidence Interval, 0.87-2.39; p = 0.148). Second, the central finding was a statistically significant, qualitative interaction between recipient neutropenia and donor hemoglobin (adjusted HR = 0.44, p for interaction = 0.013). This interaction reversed the potentially deleterious effect of hemoglobin: in the subgroup of neutropenic recipients, higher donor hemoglobin was associated with a protective trend, mitigating the profoundly poor prognosis observed in patients with isolated neutropenia. In conclusion, our study identified a novel and statistically robust interaction, suggesting that the prognostic impact of donor hemoglobin is context-dependent and fundamentally altered by the recipient's baseline immune status. While these preliminary findings provide a compelling rationale for future mechanistic studies, they require urgent validation in larger cohorts and should not be used to guide clinical donor selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.